HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Summary Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seasholtz, T. M. Articles by Brown, J. H. Search for Related Content PubMed PubMed Citation Articles by Seasholtz, T. M. Articles by Brown, J. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Medline Plus Health Information Vascular Diseases

RHO SIGNALING in Vascular Diseases

Department of Pharmacology, University of California at San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, California, 92093-0636

	SUMMARY

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
Rho signaling pathways in vascular smooth muscle cells are highly activated in hypertension, a condition associated with a variety of vascular diseases, including restenosis injury and atherosclerosis. In this review we suggest that inflammatory cytokines and agonists of G protein–coupled receptors that activate Rho are effective triggers of vascular disease. Accordingly, Rho kinase inhibitors and statins may have therapeutic potential for preventing vascular disease characterized by Rho-mediated cell proliferation and gene expression.

	INTRODUCTION

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
Appreciated as little more than a Ras homolog just a decade ago, the low-molecular-weight G protein Rho is now recognized as a formidable and versatile force in the signal transduction field. Rho signaling pathways, which likely serve homeostatic functions under normal physiological conditions, appear to be most highly activated under conditions of inflammation and injury. Whereas their recruitment may be of benefit for initiation of protective responses, their sustained activation may have pathological consequences in vascular smooth muscle. Activation of Rho in vascular smooth muscle is sufficient to produce vasoconstriction and thereby increase blood pressure; Rho also acts in concert with additional signaling pathways activated upon cell stress to produce changes in cell growth. This review will focus specifically on recent investigations of Rho signaling in vascular smooth muscle cell (VSMC) growth and a host of vascular pathophysiologies and occlusive diseases ranging from atherosclerosis to restenosis. A particular focus will be on findings that implicate increased Rho activity and signaling in a number of forms of experimental hypertension as well as in VSMC responsiveness to growth stimuli. This review will also detail the rapidly accumulating support for inhibitors of Rho signaling as important therapeutic treatments for atherosclerosis and restenosis injury.

	RHO ACTIVATION AND REGULATION

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
G proteins bind GTP and thereby become activated as signal transducers; by virtue of their inherent GTPase activities, they act as elegant molecular switches, transducing a variety of extracellular signals in a regulated fashion. The Rho subfamily of small GTPases includes RhoA, RhoB, and RhoC; RhoA is the best characterized and has been shown to be involved in cell adhesion, migration and invasion (1, 2), cell growth responses (1, 3, 4) and gene expression (5, 6). Relatively less is known about RhoB and RhoC. Interestingly, RhoB has been shown to be immediately– early inducible (7) and to inhibit cell growth and induce apoptosis (8). RhoC, on the other hand, is expressed in certain forms of cancer, and its expression has been correlated with cell invasiveness (9–10).

Under basal conditions, Rho proteins are bound to guanine nucleotide dissociation inhibitors (GDIs) in the cytosol. Activation of small G proteins occurs through stimulation of guanine nucleotide exchange factors (GEFs), which promote the release of GDP in exchange for GTP. Once activated, Rho interacts with various effectors, including PRK1/2, mDia, rhotekin and the best-characterized effector, Rho kinase (also known as ROK/ROCK-II and p160ROCK/ROCKß). GTPase-activating proteins (GAPs) interact with Rho to terminate signal transduction.

Because active Rho translocates to the membrane, Rho activation was initially determined by Western blot analysis of membrane-associated protein; the binding of radiolabeled guanine nucleotides to Rho has also been examined. Currently, the most common method for measuring Rho activation is a "pull-down" assay in which GTP-bound Rho is affinity-precipitated using the Rho binding domain (RBD) of a Rho effector and subjected to Western gel analysis (11). A limitation of these assays is that they do not readily provide kinetic or spatial information; more recently, single-cell assays implementing immunostaining of Rho–RBD binding (12) or fluorescence resonance energy transfer (FRET)-based probes have thus become key to visualizing Rho activation and its relation to defined cellular events (13). Although the literature describing the activation of RhoA has become extensive, investigations into the activation of other Rho isoforms (RhoB, RhoC) remain limited.

A number of pharmacological tools have been employed to study Rho function. These include bacterial toxins such as the C3 exoenzyme from Claustridium botulinum, which ADP-ribosylates and thereby inactivates Rho proteins, and cytotoxic necrotizing factor 1, which activates Rho by deamidating a specific Glu residue (14–16). Statins, used clinically to reduce blood cholesterol levels (17), inhibit the isoprenylation, and therefore the membrane localization, of Rho (18, 19). Such inhibition may be one of the bases for the clinical effects of the statins. Dominant-negative mutants of both Rho and Rho kinase (20, 21) have been used to demonstrate their involvement in cellular functions, and pharmacological inhibitors of Rho kinase are also commonly used to establish Rho kinase–dependence of downstream responses.

	RHO AND VASCULAR CONTRACTION

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
Vascular smooth muscle contraction is classically considered to be regulated by increases in intracellular Ca ²⁺ and activation of the Ca ²⁺ –calmodulin dependent myosin light chain kinase. This enzyme phosphorylates myosin light chain and thus promotes the cycling of actin–myosin interactions that generate contractile force. Another mechanism that contributes to the tonic component of vascular smooth muscle contraction, however, is Ca ²⁺ -sensitization, which occurs independent of increases in intracellular Ca ²⁺ and is mediated by RhoA. Among the earliest evidence for the involvement of G proteins in Ca ²⁺ -sensitization was the observation that GTP (or its stable analog GTS) could elicit contraction of permeabilized vessels when constant Ca ²⁺ levels were maintained (22, 23). Subsequently, it was discovered that C3 exoenzyme, which ADP-ribosylates and inactivates Rho isoforms, blocks Ca ²⁺ -sensitization in response to norepinephrine plus GTP in per-meabilized vessels (24). The molecular mechanisms responsible for G protein–coupled receptor (GPCR)-stimulated, Rho-mediated Ca ²⁺ -sensitization involve the Rho effector Rho kinase. Rho kinase phosphorylates the myosin-binding subunit of myosin phosphatase 1 (MYPT1) and thereby renders it inactive (25). The accumulation of phosphorylated myosin light chain would thus increase contractility, a hypothesis corroborated by the finding that the catalytic subunit of Rho kinase produces contraction when added to permeabilized rabbit portal vein (26). Similarly, the Rho kinase inhibitor Y-27632 has been shown to block agonist and guanine nucleotide–stimulated contraction of rabbit mesenteric artery (27).

	RHO AND VASCULAR SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
Although a role for Rho in GPCR-stimulated vascular smooth muscle contraction is now well established, the involvement of Rho in GPCR-stimulated VSMC proliferation and migration has only recently come to the scientific forefront. Our studies using VSMC from the rat aorta have demonstrated that thrombin-stimulated DNA synthesis and migration are inhibited by exoenzyme C3 and Y-27632 (1). Urokinase-dependent VSMC proliferation also is dependent upon Rho (4). We have additionally observed that thrombin and angiotensin II (AngII) activate RhoA in rat aortic VSMC, whereas GPCR agonists such as norepinephrine and phenlyephrine, which do not act as mitogens, fail to activate RhoA (1). Intriguingly, although thrombin activates RhoA, and Rho is necessary for thrombin-stimulated DNA synthesis in rat aortic VSMC, adenoviral transfection of cells with activated RhoA is not sufficient to induce DNA synthesis. Rather, for mitogenic signaling in VSMC, it appears that RhoA collaborates synergistically with Ras, such that DNA synthesis is activated only by agonists that stimulate both pathways. This supports earlier studies indicating that activation of Rho is critical for Ras-induced cell cycle progression (28).

A number of downstream signals generated by activation of Rho might contribute to cell cycle progression and cell proliferation. One downstream effect of Rho is to reduce expression of cell cycle inhibitors such as the cyclin-dependent kinase inhibitors p21 ^Waf1/Cip1 and p27 ^Kip1 (28). Our studies have demonstrated that adenoviral expression of a constitutively active form of RhoA in rat aortic VSMC reduces p27 ^Kip1 protein levels. Direct activation of Rho with cytotoxic necrotizing factor-1 also decreases p27 ^Kip1 and increases DNA synthesis in human smooth muscle cells (26). Conversely, cellular levels of p27 ^Kip1 are increased when Rho function is inhibited by exoenzyme C3 or treatment with statins (29, 30).

An additional mechanism underlying the ability of Rho to positively influence cell cycle progression involves cytoskeletal effects on the nuclear translocation or phosphorylation of extracellular- regulated kinase (ERK). Cytoskeletal changes, in particular stress fiber formation and cell rounding, were the first responses reported to be affected by Rho proteins (31). Serotonin stimulation of bovine pulmonary artery VSMC leads to translocation of ERK to the nucleus, and this response is inhibited by treatment with either dominant negative RhoA or the Rho kinase inhibitor Y-27632 (32). We have similarly reported that mechanical stretch of neonatal rat ventricular cardiac myocytes leads to RhoA activation and nuclear translocation of phospho-ERK. Phospho-ERK translocation is inhibited by disruption of the actin cytoskeleton with jasplakinolide or disruption of caveolae with methyl-ß-cyclodextrin (33). Although some reports suggest that it is only the translocation of activated ERK to the nucleus that is affected by Rho activation, other groups have shown that increases in ERK phosphorylation are also Rho-dependent (34–36). Of particular interest, a recent study suggests that Rho kinase signals through LIM kinase to produce stress fiber formation–dependent ERK phosphorylation, which in turn regulates the timing of cyclin D1 expression and cell cycle progression (34, 35).

	RHO AND HYPERTENSION

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
Increased total peripheral vascular resistance, a hallmark of hyper-tension, results in part from enhanced agonist-stimulated blood vessel contraction (37–39). The contraction of resistance arteries mediated by ₁ -adrenergic receptors is significantly greater in hypertension, whereas contraction stimulated by KCl (i.e., mediated by increased intracellular Ca ²⁺ ) is no different from the normotensive state (37, 38). These observations suggest that agonist- stimulated Ca ²⁺ -sensitization, a Rho-dependent process, may be enhanced in hypertension. This notion is further supported by evidence that serotonin-stimulated contraction of permeabilized coronary arteries at constant levels of Ca ²⁺ (i.e., reflecting Ca ²⁺ -sensitization) is increased in vessels from spontaneously hyper-tensive rats (SHR) (39). Another key finding implicating Rho in increased vascular resistance in vivo is that the Rho kinase inhibitor Y-27632 reduces blood pressure in three experimental forms of hypertension (27). More recently, Y-27632 was also shown to produce cerebral (basilar artery) dilation, which was significantly greater in SHR or rats made hypertensive by treatment with the nitric oxide synthase inhibitor L-NAME (N-nitro-L-arginine methyl ester) than in normotensive Wistar-Kyoto rats (WKY) (40). These studies highlight the importance of the Rho kinase pathway in blood pressure control and suggest a relationship between the extent of Rho expression/activation and blood pressure.

As indicated above, VSMC proliferation and migration are also Rho-dependent responses (1), which are likewise enhanced in hypertension. Both VSMC (41) and endothelial cells (42) from hypertensive rats have increased migratory capacity when compared to cells from normotensive rats. VSMC from SHR also exhibit a greater ability than control WKY cells to proliferate when cultured in serum or stimulated with AngII (43, 44). Hypertension is a clear risk factor for cardiovascular disorders such as restenosis, atherosclerosis, and renal failure, and VSMC proliferation and migration contribute to the pathophysiological progression of these vascular diseases. Indeed, clinical studies suggest that a number of antihypertensive therapies, although effective at lowering blood pressure, are not fully effective at reducing arteriosclerotic remodeling of resistance arteries, coronary events, and renal failure [see (45–47) ]. Thus, new molecular targets for pharmacological regulation of vascular proliferation and migration are being sought, and Rho kinase inhibitors and statins are clearly of interest for their therapeutic potential.

Both the expression of RhoA and the fraction of RhoA in the active state are increased in the vasculature of hypertensive rats; concomitantly, p27 ^Kip1 expression is reduced and rates of Rho-dependent DNA synthesis are increased (Figure 1) (48). Additional work has established that there are increases in vascular Rho(A) activation in stroke-prone SHR, renal hypertensive rats, and deoxycorticosterone acetate (DOCA)-salt hypertensive rats (49, 50), as well as in models of diabetes (51, 52). These findings lend strong support to the hypothesis that deregulation of Rho activation and signaling contribute to hypertension and a variety of associated vascular pathophysiologies.

View larger version (19K): [in this window] [in a new window]   Figure 1. Elevated DNA synthesis and RhoA activation in spontaneously hypertensive rats. A. DNA synthesis in aortic smooth muscle cells from spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats. Cells were grown to confluence and serum-starved for 24 hours and then exposed to either vehicle, thrombin (Thr,12nM) or phenylephrine (PE, 10 µM) for 48 hours and labeled with [3H]thymidine for the last five hours prior to harvest for measurement of [3 H]thymidine incorporation into DNA. [See (45).] B. RhoA activation in aortic smooth muscle cells from SHR and WKY rats is measured as outlined in the text. Cells were stimulated with vehicle, thrombin (Thr,12nM) or phenylephrine (PE, 10µM) for 3 minutes. Cells were lysed and the lysates centrifuged at 14,000 x g for two minutes. The remaining supernatant was either used for Western blot analysis for total RhoA or added to a GST-fusion protein of the Rho binding domain of the Rho effector rhotekin precoupled to glutathione beads, followed by Western blot analysis for active RhoA.

	RHO AND NITRIC OXIDE SYNTHASE: RECIPROCAL REGULATION AND ENDOTHELIAL DYSFUNCTION

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
Discovery of the prominent role of nitric oxide (NO) as a vasodilator was a critical cornerstone in explaining the known relaxant effects of nitroprusside (i.e., a generator of NO) and in identifying the endothelium-dependent relaxing factor (EDRF) as NO (53, 54). Impaired endothelial function, resulting in decreased NO production, has been implicated in the etiology of both hypertension and atherosclerosis [see (55)]. Decreased endothelial nitric oxide synthase (eNOS) expression has been reported in aortas from adult SHR (56), and blood pressure is elevated in eNOS-deficient mice (57). The delivery of the eNOS-encoding gene into the tail vein of SHR, moreover, produces a significant reduction in blood pressure (58). There is thus compelling evidence that decreased eNOS is a mediator of deregulated blood pressure in hypertension. Interestingly, there is extensive crosstalk between the regulation of NO synthesis and Rho signaling pathways. A seminal finding in this regard is that the inhibition of Rho function by statins or exonuclease C3 upregulates NOS expression (18, 59, 60), and inhibition of Rho kinase results in increased NO production (61). These observations suggest that Rho serves to limit NO synthesis (59, 60). We have additionally found that VSMC express both eNOS and nNOS. Furthermore, Rho may decrease the expression of nNOS and subsequent NO production in VSMC (unpublished observation; T. Seasholtz).

In addition to effects of Rho on NOS, there is growing evidence that the NOS pathway can affect Rho function, in particular the membrane association of RhoA (62), Rho-mediated contractile responses, and RhoA activation (63–65). The ability of the NOS pathway to inhibit VSMC proliferation, migration, and contractility (66) may also result, in part, from the direct effect of NO diffusing from endothelial cells or of NO formed within VSMC to downregulate Rho signaling. Taken together, there is strong evidence for a signaling loop between Rho and the NOS pathway(s), in which increases in vascular Rho signaling might contribute to decreases in NOS, and decreased levels of NO further elevate Rho signaling (Figure 2). Mechanistically, NOS activity may serve to protect against the enhanced contractile and proliferative changes associated with hypertension by decreasing the activity of RhoA.

View larger version (16K): [in this window] [in a new window]   Figure 2. Hypertensive implications of Rho signaling. Rho decreases the mRNA stability of eNOS, which would thereby reduce NO production and subsequent cGMP-dependent signaling; a reduction of the inhibitory effect of cGMP on Rho activation would result in increased Rho signaling. In the schematic, arrows indicate processes of activation; blunt arrows represent inhibitory processes. Because the signaling scheme contains two blunt arrows, a positive feedback loop centers around Rho, resulting in contraction, migration, and DNA synthesis.

	INFLAMMATION, VASCULAR INJURY, ATHEROSCLEROSIS AND RHO

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

	RHO ACTIVATION BY MEDIATORS OF INFLAMMATION

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
A variety of humoral factors are formed during inflammation and injury. A number of these agents directly activate Rho, whereas others have been shown by more indirect means to signal through Rho pathways. Among these agents are certain GPCR agonists, including thrombin and sphingosine-1-phosphate (S1P), and cytokines such as TNF- and IL1-ß. Of additional interest is the possibility that LDL, which accumulates in atherosclerotic lesions and undergoes oxidative modification, likewise signals through Rho. It is likely that signals from a number of these stimuli converge to affect Rho-dependent cellular responses such as gene expression and cell proliferation.

GPCR AGONISTS
A subset of agonists for GPCRs are highly effective activators of RhoA in VSMC and other tissues. Prominent among these are thrombin, thromboxane A₂ , and lysophospholipids such as lysophosphatidic acid (LPA) and S1P (1, 48, 77, 78). The receptors for these agonists couple to the G_12/13 family of heterotrimeric G proteins. Seminal work by Sternweis and colleagues first elucidated the link between G₁₃ and RhoA activation and demonstrated that G₁₃ enhances nucleotide exchange on RhoA through its interaction with a specific GEF (i.e., p115 RhoGEF) (79). Subsequent studies have suggested that the G_12/13 family of heterotrimeric G proteins are capable of interacting with other RhoGEFs (e.g., PDZRhoGEF, LARG and Dbl), and thereby activate Rho signaling pathways (80–82). A significant literature documents the acute (i.e., within minutes) activation of RhoA by GPCR agonists in a variety of tissues/cells; however, neither long-term effects of these agonists on RhoA expression and activation, nor the ability of GPCR agonists to regulate other Rho isoforms (e.g. RhoB and RhoC), have been established.

CYTOKINES
Cytokines such as TNF- also elicit acute RhoA activation (83), and TNF- stimulation of MAP kinase, endothelial permeability, and E-selectin expression have been shown to be inhibited by both Y-27632 and statins (84, 85). The mechanisms underlying the effects of TNF- on RhoA remain to be determined, because there is to our knowledge no demonstrated link between molecules in the TNF- signaling cascade and Rho GEFs or GAPs. One possibility is that TNF- activates RhoA secondary to activation of sphingosine kinase, resulting in S1P formation and signaling (86, 87). Indeed, one report suggests that TNF- –induced MCP-1 expression in response to oscillatory flow is mediated by S1P in human aortic endothelial cells (87). IL1-ß also increases nucleotide exchange on RhoA and induces C3-sensitive actin stress fiber formation in HeLa cells (88); however, in smooth muscle cells, IL1-ß treatment was found to decrease Rho activation (89).

View larger version (26K): [in this window] [in a new window]   Figure 3. Rho signaling in vascular diseases. The upregulation of vascular RhoA, observed in hypertentsion, is hypothesized to enhance VSMC proliferation and inflammation in response to injury and atherogenesis. Inflammatory mediators including GPCR agonists, cytokines, and oxidatively modified LDL (oxLDL) signal through Rho to produce a variety of cellular responses involved in cell contraction, proliferation, and inflammation. These Rho-mediated responses contribute to the development of vascular diseases. Rho acting through Rho kinase has also been suggested to produce LIM kinase– and stress fiber–dependent activation of ERK, which in turn regulates the timing of cyclin D1 expression and cell cycle progression. It is likely that inflammatory mediators signal through Rho to activate NF-B, increasing the expression of monocyte chemotactic peptide 1 (MCP-1), and adhesion molecules such as VCAM-1 and ICAM-1, leading to recruitment and adhesion of monocytes to the vascular wall. All of the signaling components mentioned above predispose to vascular disease.

Is NF-B A MEDIATOR OF RHO SIGNALING?
Nuclear factor B (NF-B) is a transcription factor that is activated in response to inflammatory stimuli. Under basal conditions, NF-B is maintained in the cytosol by virtue of its association with -B inhibitory proteins. Upon stimulation, -B is phosphorylated by -B kinase (IKK) and dissociates from NF-B; consequently, NF-B enters the nucleus, where it can induce inflammatory genes such as those that encode MCP-1, VCAM-1, and ICAM-1. Phosphorylated -B is then polyubiquitinated and proteosomally degraded [ see (98, 99)].

Cytokines such as TNF- and IL1-ß are well-known activators of NF-B, as are GPCR agonists that couple to G_12/13 and Rho signaling pathways (100–102). Furthermore, there is recent evidence suggesting that both GPCR- and TNF-–stimulated NF-B activation depend upon Rho signaling. For example, fMet-Leu- Phe (fMLP; i.e., a GPCR agonist) stimulates expression of an NF-B–sensitive reporter gene, and this can be prevented by over-expression of a dominant-negative form of RhoA (103); bradykin-mediated NF-B activation is likewise blocked by inhibition of Rho by C3 (100, 104); blocking Rho function with exoenzyme C3 prevents TNF- stimulated nuclear translocation of NB (105). Despite evidence for Rho involvement, the me chanism by which Rho activates IKK and/or NF-B has yet to be elaborated. Some studies have addressed the question of whether Rho signals through Rho kinase or another Rho effector to mediate NF-B activation, but conclusions in the literature are conflicting (105, 106).

A link between NF-B and VSMC proliferation is suggested by the observation that cytokine gene expression and VSMC proliferation are inhibited by overexpression of a proteosome-resistant form of -B (107). A separate study has demonstrated that the proteosome-resistant form of -B can reduce neointima formation following vascular injury (108). Because TNF- and IL1-ß increase VSMC proliferation and expression of MCP-1, VCAM-1, and ICAM-1, and because these responses are mediated in part through Rho and NF-B signaling, these intermediates could be important therapeutic targets for vascular diseases.

	CONCLUSIONS

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
Under conditions of vascular inflammation, diverse inflammatory mediators are released that activate RhoA. Multiple lines of evidence suggest that enhanced Rho activation is involved in hypertension and that Rho may act, in this context, to downregulate cyclin-dependent kinase inhibitors and NOS, as well as to activate ERK- and NF-B–mediated gene expression. We hypothesize that increases in RhoA activity that occur in hypertension predispose to enhanced vascular proliferation, migration, and inflammation in response to injury and lipid deposition. Future studies utilizing transgenic and gene deletion technology will help determine whether increases in VSMC RhoA activity are necessary or sufficient to produce hypertension or mediate responses to vascular injury. In addition, human pharmacogenomic studies could identify polymorphisms in Rho signaling molecules or specific patients in whom Rho signaling is dysregulated. Numerous findings implicating Rho in vascular responses highlight the potential therapeutic importance of components of the Rho signaling pathway as targets for the treatment of vascular diseases.

Tammy M. Seasholtz, PhD, is Assistant Adjunct Professor in the Department of Pharmacology at the University of California at San Diego School of Medicine. Address correspondence to TMS. E-mail tseasholtz{at}ucsd.edu; fax 858-534-4337.

Joan Heller Brown, PhD, is Professor and Chair of the Department of Pharmacology at The University of California at San Diego School of Medicine.

	ACKNOWLEDGMENTS

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 
TMS is supported by an American Heart Association National Center Research Program Scientist Development Grant. JHB is supported for the work on this project by NIH Grant GM 36927. The authors would like to thank Dr. James Liao (Harvard Medical School), and Dr. Yury Miller and Dr. Julie Radeff-Huang (UCSD) for their advice and comments regarding the manuscript.

	References

TOP Summary Introduction Rho Activation and Regulation Rho and Vascular Contraction Rho and Vascular Smooth... Rho and Hypertension Rho and Nitric Oxide... Inflammation, Vascular Injury,... Rho Activation by Mediators... Conclusions References

 

1. Seasholtz, T.M., Majumdar, M., Kaplan, D.D., and Brown, J.H. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ. Res. 84, 1186–1193 (1999). This paper is the first to demonstrate Rho involvement in GPCR-stimulated vascular proliferation and migration.[Abstract/Free Full Text]
2. Sander, E.E. and Collard, J.G. Rho-like GTPases: Their role in epithelial cell–cell adhesion and invasion. Eur. J. Cancer 35, 1302–1308 (1999).
3. Majumdar, M., Seasholtz, T.M., Goldstein, D., de Lanerolle, P., and Brown, J.H. Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis. J. Biol. Chem. 273, 10099–10106 (1998).[Abstract/Free Full Text]
4. Sauzeau, V., Le Mellionnec, E., Bertoglio, J., Scalbert, E., Pacaud, P., and Loirand, G. Human urotensin II–induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho kinase. Circ. Res. 88, 1102–1104 (2001).[Abstract/Free Full Text]
5. Treisman, R., Alberts, A.S., and Sahai, E. Regulation of SRF activity by Rho family GTPases. Cold Spring Harb. Symp. Quant. Biol. 63, 643–651 (1998).[CrossRef][Medline]
6. Morissette, M. R., Sah, V.P., Glembotski, C.C., and Brown, J.H. The Rho effector, PKN, regulates ANF gene transcription in cardiomyocutes through a serum response element. Am. J. Physiol. 278, H1769–H1774 (2000).
7. Fritz, G and Kaina, B. Transcriptional activation of the small GTPase gene RhoB by genotoxic stress is regulated via a CCAAT element. Nucleic Acids Res. 29, 792–798 (2001).[Abstract/Free Full Text]
8. Chen, Z., Sun, J., Pradines, A., Favre, G., Adnane, J., and Sebti, S. M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275, 17974–17978 (2000).[Abstract/Free Full Text]
9. Suwa, H., Ohshio, G., Imamura, T., Watanabe, G., Arii, S., Imamura, M., Narumiya, S., Hiai, H., and Fukumoto, M. Overexpression of the rhoC gene correlates with progression of duodenal adenocarcinoma of the pancreas. Br. J. Cancer 77, 147–152 (1998).[Medline]
10. van Golen, K.L., Davies, S., Wu, Z.F. et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin. Cancer Res. 5, 2511–2519 (1999).[Abstract/Free Full Text]
11. Ren, X.D., Kiosses, W. B., and Schwartz, M. A. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 18, 578–585 (1999). This study provides evidence for a relationship between cell adhesion and Rho activation and establishes the utility of an RBD pull down assay now widely used to assay Rho activation.[CrossRef][Medline]
12. Dubreuil, C. I., Winton, M.J., and McKerracher, L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 162, 233–243 (2003).[Abstract/Free Full Text]
13. Yoshizaki, H., Ohba, Y., Kurokawa, K., Itoh, R.E., Nakamura, T., Mochizuchi, N., Nagashima, K., and Matsuda, M. Activity of Rho-family GTPases during cell division as visualized with FRET-based probes. J. Cell Biol. 162, 223–232 (2003).[Abstract/Free Full Text]
14. Schmidt, G. and Aktories, K. Bacterial cytotoxins target Rho GTPases. Naturwissenschaften 85, 253–261 (1998).[CrossRef][Medline]
15. Schmidt, G., Sehr, P., Wilm, M., Selzer, J., Mann, M., and Aktories, K. Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1. Nature 387, 725–729 (1997).[CrossRef][Medline]
16. Lerm, M., Schmidt, G., Goehring, U. M., Schirmer, J., and Aktories, K. Identification of the region of Rho involved in substrate recognition by Escherichia coli cytotoxic necrotizing factor 1 (CNF1). J. Biol. Chem. 274, 28999–29004 (1999).[Abstract/Free Full Text]
17. Halcox, J.P. and Deanfield, J.E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109, II42–II48 (2004).
18. Laufs, U. and Liao, J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266–24271 (1998). This paper establishes that Rho activation decreases eNOS mRNA stability and that statin treatment increases eNOS mRNA stability.[Abstract/Free Full Text]
19. Chica, I., Schneiderhan-Marra, N., Yilmaz, A., Garlichs, C.D., and Goppelt-Struebe, M. Monitoring the cellular effects of HMG-CoA Reductase Inhibitors in vitro and ex vivo. Arterioscler. Thromb. Vasc. Biol. 24, 2046–2050 (2004).[Abstract/Free Full Text]
20. Oshiro, N., Fukata, Y., and Kaibuchi, K. Phosphorylation of moesin by Rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J. Biol. Chem. 273, 34663–34666 (1998).[Abstract/Free Full Text]
21. Amano, M., Chihara, K., Nakamura, N., Fukata, Y., Yano, T., Shibata, M., Ikebe, M., and Kaibuchi, K. Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase. Genes Cells 3, 177–188 (1998).[Abstract]
22. Nishimura, J., Kolber, M., and van Breemen, C. Norepinephrine and GTPS increase myofilament Ca ²⁺ sensitivity in -toxin permeabilized arterial smooth muscle. Biochem. Biophys. Res. Commun. 157, 677–683 (1988). This paper describes guanine nucleotide involvement in the phenomenon of Ca ²⁺ sensitization.[CrossRef][Medline]
23. Kitazawa, T., Kobayashi, S., Horiuti, K., Somlyo, A.V., and Somlyo, A.P. Receptor-coupled, permeabilized smooth muscle. Role of the phosphatidylinositol cascade, G-proteins, and modulation of the contractile response to Ca ²⁺ . J. Biol. Chem. 264, 5229–5342 (1989). This paper provides evidence for a G protein–coupled pathway mediating Ca ²⁺ sensitivity of vascular contractility.
24. Kokubu, N., Satoh, M., and Takayanagi, I. Involvement of botulinum C3- sensitive GTP-binding proteins in ₁ -adrenoceptor subtypes mediating Ca ²⁺ -sensitization. Eur. J. Pharmacol. 290, 19–27 (1995).[CrossRef][Medline]
25. Kimura, K., Ito, M., Amano, M.et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245–248 (1996). This work demonstrates that Rho and Rho kinase phosphorylate and inhibit myosin phosphatase.[Abstract]
26. Kureishi, Y., Kobayashi, S., Amano, M., Kimura, K., Kanaide, H., Nakano, T., Kaibuchi, K., and Ito, M. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J. Biol. Chem. 272, 12257–12260 (1997).[Abstract/Free Full Text]
27. Uehata, M., Ishizaki, T., Satoh, H. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990–994 (1997). Seminal work that showed inhibition of Rho kinase reduced blood pressure in multiple forms of experimental hypertension.[CrossRef][Medline]
28. Olson, M.F., Paterson, H.F., and Marshall, C.J. Signals from Ras and Rho GTPases interact to regulate expression of p21 ^Waf1/Cip1 . Nature 394, 295–299 (1998). This work demonstrated a role for Rho in decreasing cyclin dependent kinase inhibitors, thereby allowing for cell cycle progression.[CrossRef][Medline]
29. Laufs, U., Marra, D., Node, K., and Liao, J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27Kip1. J. Biol. Chem. 274, 21926–21931 (1999). This paper demonstrates that the ability of statins to decrease VSMC proliferation are related to inhibition of Rho function.[Abstract/Free Full Text]
30. Hirai, A., Nakamura, S., Noguchi, Y., Yasuda, T., and Kitagawa, M. Geranylgeranylated Rho small GTPase(s) are essential for the degradation of p27 ^Kip1 and facilitate the progression from G₁ to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272, 13–16 (1997).[Abstract/Free Full Text]
31. Ridley, A.J. and Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389–399 (1992).[CrossRef][Medline]
32. Liu, Y., Suzuki, Y.J., Day, R.M., and Fanburg, B. L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Ci rc. Res. 95, 579–586 (2004).
33. Kawamura, S., Miyamoto, S., and Brown, J. H. Initiation and transduction of stretch-induced RhoA and Rac1 activation through caveolae: cytoskeletal regulation of ERK translocation. J. Biol. Chem. 278, 31111–31117 (2003).[Abstract/Free Full Text]
34. Welsh, C. F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M. A., and Assoian, R. K. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 3, 950–957 (2001).[CrossRef][Medline]
35. Roovers, K., Klein, E A., Castagnino, P., and Assoian, R.K. Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression. Dev. Cell 5, 273–284 (2003).[CrossRef][Medline]
36. Krepinsky, J.C., Ingram, A.J., Tang, D., Wu, D., Liu, L., and Scholey, J.W. Nitric oxide inhibits stretch-induced MAPK activation in mesangial cells through RhoA inactivation. J. Am. Soc. Nephrol. 14, 2790–2800 (2003).[Abstract/Free Full Text]
37. Vila, E., Tabernero, A., and Ivorra, M.D. Inositol phosphate formation and contractile response linked to ₁ -adrenoceptor in tail artery and aorta from spontaneously hypertensive and Wistar-Kyoto rats. J. Cardiovasc. Pharmacol. 22, 191–197 (1993).[Medline]
38. Aqel, M.B., Sharma, R.V., and Bhalla, R.C. Increased Ca ²⁺ sensitivity of ₁ -adrenoceptor-stimulated contraction in SHR caudal artery. Am. J. Physiol. 250, C275–C282 (1986). This study demonstates increased agonist, but not KCl (Ca ²⁺ -mediated) contraction in vessels from SHR, suggesting differences in Ca2+ sensitization.
39. Satoh, S., Kreutz, R., Wilm, C., Ganten, D., and Pfitzer, G. Augmented agonist-induced Ca ²⁺ sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. J. Clin. Invest. 94, 1397–1403 (1994).
40. Chrissolis, S. and Sobey, C.G. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension. Circ. Res. 88, 774–779 (2001).[Abstract/Free Full Text]
41. Hsieh, C.-C. and Lau, Y.-T. Migration of vascular smooth muscle cells is enhanced in cultures derived from spontaneously hypertensive rat. Pflugers Arch. 435, 286–292 (1998).[CrossRef][Medline]
42. Isogai, N., Fujii, S., Tsukahara, T., and Kamiishi, H. Effect of hypertension on arterial structure and wound repair at the microvascular anastamosis site using stroke-prone spontaneously hypertensive rats (SHRSP). Microsurgery 14, 501–507 (1993).[Medline]
43. Paquet, J.-L., Baudouin-Legros, M., Brunelle, G., and Meyer, P. Angiotensin II–induced proliferation of aortic myocytes in spontaneously hypertensive rats. J. Hypertens. 8, 565–572 (1990).[Medline]
44. Morton, C., Baines, R., Masood, I., Ng, L., and Boarder, M.R. Stimulation of two vascular smooth muscle-derived cell lines by angiotensin II: Differential second messenger responses leading to mitogenesis. Br. J. Pharmacol. 115, 361–367 (1995).[Medline]
45. Weber, M.A. Translating data on antihypertensive drugs into clinical practice. American J. Hypertens. 11, 89S–94S (1998).[CrossRef]
46. Turner, S.T. and Boerwinkle, E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics. 4, 53–65 (2003).[CrossRef][Medline]
47. Schiffrin, E. L. Beyond blood pressure: the endothelium and atherosclerosis progression. Am. J. Hypertens. 15, 115S–122S (2002).[CrossRef][Medline]
48. Seasholtz, T.M., Zhang, T., Morissette, M.R., Howes, A.L., Yang, A.H., and Brown, J.H. Increased expression and activity of RhoA is associated with increased DNA synthesis and reduced p27 ^Kip1 expression in the vasculature of hypertensive rats. Circ. Res. 89, 488–495 (2001). This study is the first to report upregulation of Rho activity in vessels and VSMC from hypertensive rats.[Abstract/Free Full Text]
49. Seko, T., Ito, M., Kureishi, Y., Okamoto, R., Moriki, N., Onishi, K., Isaka, N., Hartshorne, D. J., and Nakano, T. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92, 411–418 (2003).[Abstract/Free Full Text]
50. Moriki, N., Ito, M., Seko, T. et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens. Res. 27, 263–270 (2004).[CrossRef][Medline]
51. Massey, A. R., Miao, L., Smith, B.N., Liu, J., Kusaka, I., Zhang, J.H., and Tang, J. Increased RhoA translocation in renal cortex of diabetic rats. Life Sci. 72, 2943–2952 (2003).[CrossRef][Medline]
52. Miao, L., Calvert, J.W., Tang, J., and Zhang, J.H. Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats. Life Sci. 71, 1175–1185 (2002).[CrossRef][Medline]
53. Martin, W., Villani, G.M., Jothianandan, D., and Furchgott, R.F. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J. Pharmacol. Exp.Ther. 232, 708–716 (1985).[Abstract/Free Full Text]
54. Ignarro, L. J., Buga, G.M., Wood, K.S., Byrns, R.E., and Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84, 9265–9269 (1987).[Abstract/Free Full Text]
55. John, S. and Schmieder, R.E. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J. Hypertens. 18, 363–374 (2000).[CrossRef][Medline]
56. Chou, T.C., Yen, M.H., and Li, C.Y. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 31, 643– 648 (1998).[Abstract/Free Full Text]
57. Huang, P.L., Huang, Z., Mashimo, H., Bloch, K.D., Moskowitz, M.A., Bevan, J.A., and Fishman, M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239–242 (1995).[CrossRef][Medline]
58. Lin, K.F., Chao, L., and Chao, J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 30, 307–313 (1997).[Abstract/Free Full Text]
59. Chen, H., Ikeda, U., Shimpo, M., Ikeda, M., Minota, S., and Shimada, K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 36, 923–928 (2000).[Abstract/Free Full Text]
60. Muniyappa, R., Xu, R., Ram, J.L, and Sowers, J.R. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am. J. Physiol. 278, H1762–H1768 (2000).
61. Wolfrum, S., Dendorfer, A., Rikitake, Y., Stalker, T.J., Gong, Y., Scalia, R., Dominiak, P., and Lioa, J.K. Inhibition of Rho-kinase leads to a rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arteroslcer. Thromb. Vasc. Biol. 24, 1842–1847 (2004).[Abstract/Free Full Text]
62. Sawada, N., Itoh, H., Yamashita, J. et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem. Biophys. Res. Commun. 280, 798–805 (2001).[CrossRef][Medline]
63. Gohla, A., Schultz, G., and Offermanns, S. Role for G12/G13 in agonist-imduce vascular smooth muscle cell contraction. Circ. Res. 87, 221–227 (2000).[Abstract/Free Full Text]
64. Sauzeau, V., Le Jeune, H., Cario-Toumaniantz, C., Smolenski, A., Lohmann, S. M., Bertoglio, J., Chardin, P., Pacaud, P., and Loirand, G. Cyclic GMP–dependent protein kinase signaling pathway inhibits RhoA-induced Ca ²⁺ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 275, 21722–21729 (2000). This work demonstrates an important link between cGMP and inhibition of Rho function.[Abstract/Free Full Text]
65. Gudi, T., Chen, J.C., Casteel, D.E., Seasholtz, T.M., Boss, G.R., and Pilz, R.B. cGMP-dependent protein kinase inhibits serum-response element-dependent transcription by inhibiting rho activation and functions. J. Biol. Chem. 277, 37382–37393 (2002).[Abstract/Free Full Text]
66. Barbato, J. E. and Tzeng, E. Nitric oxide and arterial disease. J. Vasc. Surg. 40, 187–193 (2004).[CrossRef][Medline]
67. Suzuki, J., Izawa, A., and Isobe, M. Anti-vascular cell adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies inhibit neointimal hyperplasia in the murine model of arterial injury. Acta. Cardiol. 59, 147–152 (2004).[CrossRef][Medline]
68. Negoro, N., Hoshiga, M., Seto, M. et al. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 262, 211–215 (1999).[CrossRef][Medline]
69. Sawada, N., Itoh, H., Ueyama, K. et al. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101, 2030–2033 (2000). This study suggests that Rho kinase is involved in the pathophysiology of vascular injury.[Abstract/Free Full Text]
70. Shibata, R., Kai, H., Seki, Y., Kato, S., Morimatsu, M., Kaibuchi, K., and Imaizumi, T. Role of Rho-Associated Kinase in Neointima Formation After Vascular Injury. Circulation 103, 284–289 (2001).[Abstract/Free Full Text]
71. Matsumoto, Y., Uwatoku, T., Oi, K. et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: Involvement of multiple mechanisms. Arterioscler. Thromb. Vasc. Biol. 24, 181–186 (2004).[Abstract/Free Full Text]
72. Eto, Y., Shimokawa, H., Hiroki, J. et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am. J. Physiol. Heart. Circ. Physiol. 278, H1744–H1750 (2000).[Abstract/Free Full Text]
73. Mallat, Z., Gojova, A., Sauzeau, V. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res. 93, 884–888 (2003). These data provide evidence that Rho signaling is involved in atherosclerosis.[Abstract/Free Full Text]
74. Kataoka, C., Egashira, K., Inoue, S. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39, 245–250 (2002).[Abstract/Free Full Text]
75. Herdeg, C., Fitzke, M., Oberhoff, M., Baumbach, A., Schroeder, S., and Karsch, K.R. Effects of atorvastatin on instent stenosis in normo- and hypercholesterolemic rabbits. Int. J. Cardiol. 91, 59–69 (2003).[CrossRef][Medline]
76. Ni, W., Egashira, K., Kataoka, C., Kitamoto, S., Koyanagi, M., Inoue, S., and Takeshita, A. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res. 89, 415–421 (2001).[Abstract/Free Full Text]
77. Sagi, S.A., Seasholtz, T.M., Kobiashvilla, M., Wilson, B.A., Toksoz, D., and Brown, J.H. Physical and functional interactions of Gaq with Rho and its exchange factors. J. Biol. Chem. 276, 15445–15452 (2001).[Abstract/Free Full Text]
78. Seasholtz, T.M., Radeff-Huang, J., Sagi, S.A., Matteo, R.G., Weems, J.M., Stoudt, A., Buckmaster, C., Feramisco, J., and Brown, J.H. Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2. J. Neurochem. 91, 501–12 (2004).[CrossRef][Medline]
79. Hart, M. J., Jiang, X., Kozasa, T., Roscoe, W., Singer, W. D., Gilman, A. G., Sternweis, P. C., and Bollag, G. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by G1₁₃ . Science 280, 2112–2114 (1998).[Abstract/Free Full Text]
80. Fukuhara, S., Murga, C., Zohar, M., Igishi, T., and Gutkind, J.S. A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J. Biol. Chem. 274, 5868–5879 (1999).[Abstract/Free Full Text]
81. Fukuhara, S., Chikumi, H., and Gutkind, J.S. Leukemia-associated Rho guanine nucleotide exchange factor (LARG) links heterotrimeric G proteins of the G₁₂ family to Rho. FEBS Lett. 485, 183–188 (2000).[CrossRef][Medline]
82. Jin, S. and Exton, J. H. Activation of RhoA by association of Galpha(13) with Dbl. Biochem. Biophys. Res. Commun. 277, 718–721 (2000).[CrossRef][Medline]
83. Hunter, I., Cobban, H.J., Vandenabeele, P., MacEwan, D.J., and Nixon, G.F. Tumor necrosis factor-alpha-induced activation of RhoA in airway smooth muscle cells: Role in the Ca ²⁺ sensitization of myosin light chain20 phosphorylation. Mol. Pharmacol. 63, 714–721 (2003).[Abstract/Free Full Text]
84. Nwariaku, F.E., Rothenbach, P., Liu, Z., Zhu, X., Turnage, R.H., and Terada, L.S. Rho inhibition decreases TNF-induced endothelial MAPK activation and monolayer permeability. J. Appl. Physiol. 95, 1889–1895 (2003).[Abstract/Free Full Text]
85. Nubel, T., Dippold, W., Kleinert, H., Kaina, B., and Fritz, G. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J. 18, 140–142 (2004).[Abstract/Free Full Text]
86. Xia, P., Wang, L., Gamble, J.R., and Vadas, M.A. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J. Biol. Chem. 274, 34499–34505 (1999).[Abstract/Free Full Text]
87. Chen, X.-L., Grey, J.Y., Thomas, S., Qui, F.-H., Medford, R.M., Wasserman, M.A., and Kunsch, C. Sphringosine kinase-1 mediates TNF--induced MCP-1 gene expression in endothelial cells: upregulation by oscillatory flow. Am. J. Physiol. 287, H1452–H1458 (2004).
88. Singh, R., Wang, B., Shirvaikar, A., Khan, S., Kamat, S., Schelling, J.R., Konieczkowski, M., and Sedor, J.R. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J. Clin. Invest. 103, 1561–1570 (1999).[Medline]
89. John, G.R., Chen, L., Rivieccio, M.A., Melendez-Vasquez, C.V., Hartley, A., and Brosnan, C.F. Interleukin-1beta induces a reactive astroglial phenotype via deactivation of the Rho GTPase-Rock axis. J. Neurosci. 24, 2837–2845 (2004).[Abstract/Free Full Text]
90. Miller, Y.I., Viriyakosol, S., Binder, C.J., Feramisco, J. R., Kirkland, T.N., and Witztum, J.L. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278, 1561–1568 (2003).[Abstract/Free Full Text]
91. Auge, N., Nikolova-Karakashian, M., Carpentier, S., Parthasarathy, S., Negre-Salvayre, A., Salvayre, R., Merrill, A. H., Jr., and Levade, T. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphin-gomyelinase, ceramidase, and sphingosine kinase. J. Biol. Chem. 274, 21533–21538 (1999).[Abstract/Free Full Text]
92. Schaefer, C.A., Kuhlmann, C.R., Gast, C. et al. Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholine-induced proliferation of human endothelial cells. Vascul. Pharmacol. 41, 67–73 (2004).[CrossRef][Medline]
93. Galle, J., Mameghani, A., Bolz, S.S. et al. Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA. J. Am. Soc. Nephrol. 14, 1471–1479 (2003).[Abstract/Free Full Text]
94. Napoli, C., Lerman, L.O., de Nigris, F., Loscalzo, J., and Ignarro, L.J. Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells. J. Am. Coll. Cardiol. 40, 1515–1522 (2002).[Abstract/Free Full Text]
95. Siess, W., Zangl, K. J., Essler, M., Bauer, M., Brandl, R., Corrinth, C., Bittman, R., Tigyi, G., and Aepfelbacher, M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. U.S.A. 96, 6931–6936 (1999).[Abstract/Free Full Text]
96. Auge, N., Garcia, V., Maupas-Schwalm, F., Levade, T., Salvayre, R., and Negre-Salvayre, A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler. Thromb. Vasc. Bio.l 22, 1990–1995 (2002).[Abstract/Free Full Text]
97. Auge, N., Andrieu, N., Negre-Salvayre, A., Thiers, J.C., Levade, T., and Salvayre, R. The sphingomyelinceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J. Biol. Chem. 271, 19251–19255 (1996).[Abstract/Free Full Text]
98. Senftleben, U. and Karin, M. The IKK/NF-kappaB pathway. Crit. Care. Med. 30, S18–S26 (2002).[CrossRef][Medline]
99. Li, X. and Stark, G. R. NFkappaB-dependent signaling pathways. Exp. Hematol. 30, 285–296 (2002).[CrossRef][Medline]
100. Pan, Z.K., Ye, R.D., Christiansen, S.C., Jagels, M.A., Bokoch, G.M., and Zuraw, B.L. Role of the Rho GTPase in bradykinin-stimulated Nuclear Factor-kB activation and IL-ß gene expression in cultured human epithelial cells. J. Immunol. 160, 3038–3045 (1998).[Abstract/Free Full Text]
101. Siehler, S., Wang, Y., Fan, X., Windh, R. T., and Manning, D. R. Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors. Activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells. J. Biol. Chem. 276, 48733–48739 (2001).[Abstract/Free Full Text]
102. Shepard, L.W., Yang, M., Xie, P., Browning, D.D., Voyno-Yasenetskaya, T., Kozasa, T., and Ye, R.D. Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus involve G alpha(13) and RhoA. J. Biol. Chem. 276, 45979–45987 (2001).[Abstract/Free Full Text]
103. Chen, L.Y., Ptasznik, A., and Pan, Z.K. RhoA and Rac1 signals in fMLP-induced NF-kappaB activation in human blood monocytes. Biochem. Biophys. Res. Commun. 319, 629–635 (2004).[CrossRef][Medline]
104. Chen, L.Y., Zuraw, B.L., Ye, R.D., and Pan, Z.K. A Rho exchange factor mediates fMet-Leu-Phe-induced NF-kappaB activation in human peripheral blood monocytes. J. Biol. Chem. 279, 7208–7212 (2004).[Abstract/Free Full Text]
105. Hippenstiel, S., Schmeck, B., Seybold, J., Krull, M., Eichel-Streiber, C., and Suttorp, N. Reduction of tumor necrosis factor-alpha (TNF-alpha) related nuclear factor-kappaB (NF-kappaB) translocation but not inhibitor kappa-B (Ikappa-B)-degradation by Rho protein inhibition in human endothelial cells. Biochem. Pharmacol. 64, 971–977 (2002).[CrossRef][Medline]
106. Segain, J.P., Raingeard, d. l.B., Sauzeau, V. et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: Evidence in Crohn’s disease and experimental colitis. Gastroenterology 124, 1180–1187 (2003).[CrossRef][Medline]
107. Wang, Z., Castresana, M.R., Detmer, K., and Newman, W.H. An IkappaB-alpha mutant inhibits cytokine gene expression and proliferation in human vascular smooth muscle cells. J. Surg. Res. 102, 198–206 (2002).[CrossRef][Medline]
108. Zuckerbraun, B.S., McCloskey, C.A., Mahidhara, R.S., Kim, P.K., Taylor, B.S., and Tzeng, E. Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. J. Vasc. Surg. 38, 812–819 (2003).[CrossRef][Medline]

This article has been cited by other articles:

				M. Lohn, O. Plettenburg, Y. Ivashchenko, A. Kannt, A. Hofmeister, D. Kadereit, M. Schaefer, W. Linz, M. Kohlmann, J.-M. Herbert, et al. Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor Hypertension, September 1, 2009; 54(3): 676 - 683. [Abstract] [Full Text] [PDF]

				M.-H. Kim, F.-R. E. Curry, and S. I. Simon Dynamics of neutrophil extravasation and vascular permeability are uncoupled during aseptic cutaneous wounding Am J Physiol Cell Physiol, April 1, 2009; 296(4): C848 - C856. [Abstract] [Full Text] [PDF]

				C. T. Walsh, J. Radeff-Huang, R. Matteo, A. Hsiao, S. Subramaniam, D. Stupack, and J. H. Brown Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61 FASEB J, November 1, 2008; 22(11): 4011 - 4021. [Abstract] [Full Text] [PDF]

				C. T. Walsh, D. Stupack, and J. H. Brown G Protein-Coupled Receptors Go Extracellular: RhoA Integrates the Integrins Mol. Interv., August 1, 2008; 8(4): 165 - 173. [Abstract] [Full Text] [PDF]

				T. Machida, Y. Hamaya, S. Izumi, Y. Hamaya, K. Iizuka, Y. Igarashi, M. Minami, R. Levi, and M. Hirafuji Sphingosine 1-Phosphate Inhibits Nitric Oxide Production Induced by Interleukin-1{beta} in Rat Vascular Smooth Muscle Cells J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 200 - 209. [Abstract] [Full Text] [PDF]

				M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Hasko, L. Liaudet, J. W. Huffman, A. Csiszar, Z. Ungvari, K. Mackie, S. Chatterjee, et al. CB2-receptor stimulation attenuates TNF-{alpha}-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2210 - H2218. [Abstract] [Full Text] [PDF]

				S. Camino-Lopez, V. Llorente-Cortes, J. Sendra, and L. Badimon Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells Cardiovasc Res, January 1, 2007; 73(1): 208 - 216. [Abstract] [Full Text] [PDF]

				H. Ohtsu, H. Suzuki, H. Nakashima, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells Hypertension, October 1, 2006; 48(4): 534 - 540. [Full Text] [PDF]

				B. Munoz-Garcia, J. L. Martin-Ventura, E. Martinez, S. Sanchez, G. Hernandez, L. Ortega, A. Ortiz, J. Egido, and L. M. Blanco-Colio Fn14 Is Upregulated in Cytokine-Stimulated Vascular Smooth Muscle Cells and Is Expressed in Human Carotid Atherosclerotic Plaques: Modulation by Atorvastatin Stroke, August 1, 2006; 37(8): 2044 - 2053. [Abstract] [Full Text] [PDF]

				Y. Zeng, S. Zhuang, J. Gloddek, C.-C. Tseng, G. R. Boss, and R. B. Pilz Regulation of cGMP-dependent Protein Kinase Expression by Rho and Kruppel-like Transcription Factor-4 J. Biol. Chem., June 23, 2006; 281(25): 16951 - 16961. [Abstract] [Full Text] [PDF]

				T. M. Seasholtz, J. Wessel, F. Rao, B. K. Rana, S. Khandrika, B. P. Kennedy, E. O. Lillie, M. G. Ziegler, D. W. Smith, N. J. Schork, et al. Rho Kinase Polymorphism Influences Blood Pressure and Systemic Vascular Resistance in Human Twins: Role of Heredity Hypertension, May 1, 2006; 47(5): 937 - 947. [Abstract] [Full Text] [PDF]

				J. H. Brown, D. P. Del Re, and M. A. Sussman The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits Circ. Res., March 31, 2006; 98(6): 730 - 742. [Abstract] [Full Text] [PDF]

				R. H. P. Hilgers and R. C. Webb Molecular Aspects of Arterial Smooth Muscle Contraction: Focus on Rho Experimental Biology and Medicine, December 1, 2005; 230(11): 829 - 835. [Abstract] [Full Text] [PDF]

This Article Summary Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seasholtz, T. M. Articles by Brown, J. H. Search for Related Content PubMed PubMed Citation Articles by Seasholtz, T. M. Articles by Brown, J. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Medline Plus Health Information Vascular Diseases